Potential for combined therapy with 348u87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir‐resistant herpes simplex virus infection
S. Safrin, T. Schacker, J. Delehanty, E. Hill, L. Corey
Dive into the research topics of 'Potential for combined therapy with 348u87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir‐resistant herpes simplex virus infection'. Together they form a unique fingerprint.